These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12819115)

  • 1. Antigen processing of the heptavalent pneumococcal conjugate vaccine carrier protein CRM(197) differs depending on the serotype of the attached polysaccharide.
    Leonard EG; Canaday DH; Harding CV; Schreiber JR
    Infect Immun; 2003 Jul; 71(7):4186-9. PubMed ID: 12819115
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antigen processing of glycoconjugate vaccines; the polysaccharide portion of the pneumococcal CRM(197) conjugate vaccine co-localizes with MHC II on the antigen processing cell surface.
    Lai Z; Schreiber JR
    Vaccine; 2009 May; 27(24):3137-44. PubMed ID: 19446183
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B- and T-cell immune responses to pneumococcal conjugate vaccines: divergence between carrier- and polysaccharide-specific immunogenicity.
    McCool TL; Harding CV; Greenspan NS; Schreiber JR
    Infect Immun; 1999 Sep; 67(9):4862-9. PubMed ID: 10456942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotype of Streptococcus pneumoniae capsular polysaccharide can modify the Th1/Th2 cytokine profile and IgG subclass response to pneumococal-CRM(197) conjugate vaccines in a murine model.
    Mawas F; Feavers IM; Corbel MJ
    Vaccine; 2000 Dec; 19(9-10):1159-66. PubMed ID: 11137252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant variation in serotype-specific immunogenicity of the seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197 conjugate vaccine occurs despite vigorous T cell help induced by the carrier protein.
    Kamboj KK; Kirchner HL; Kimmel R; Greenspan NS; Schreiber JR
    J Infect Dis; 2003 May; 187(10):1629-38. PubMed ID: 12721943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group.
    O'Brien KL; Swift AJ; Winkelstein JA; Santosham M; Stover B; Luddy R; Gootenberg JE; Nold JT; Eskenazi A; Snader SJ; Lederman HM
    Pediatrics; 2000 Nov; 106(5):965-72. PubMed ID: 11061761
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of previous vaccination with pneumococcal conjugate vaccine on pneumococcal polysaccharide vaccine antibody responses.
    Schaballie H; Wuyts G; Dillaerts D; Frans G; Moens L; Proesmans M; Vermeulen F; De Boeck K; Meyts I; Bossuyt X
    Clin Exp Immunol; 2016 Aug; 185(2):180-9. PubMed ID: 26939935
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunogenicity differences of a 15-valent pneumococcal polysaccharide conjugate vaccine (PCV15) based on vaccine dose, route of immunization and mouse strain.
    Caro-Aguilar I; Indrawati L; Kaufhold RM; Gaunt C; Zhang Y; Nawrocki DK; Giovarelli C; Winters MA; Smith WJ; Heinrichs J; Skinner JM
    Vaccine; 2017 Feb; 35(6):865-872. PubMed ID: 28087148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
    Skinner JM; Indrawati L; Cannon J; Blue J; Winters M; Macnair J; Pujar N; Manger W; Zhang Y; Antonello J; Shiver J; Caulfield M; Heinrichs JH
    Vaccine; 2011 Nov; 29(48):8870-6. PubMed ID: 21964055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polysaccharide conjugate vaccine protein carriers as a "neglected valency" - Potential and limitations.
    Bröker M; Berti F; Schneider J; Vojtek I
    Vaccine; 2017 Jun; 35(25):3286-3294. PubMed ID: 28487056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pneumococcal polysaccharide-protein CRM197 conjugate vaccines, 7- or 9-valent, in the 2 + 1 schedule.
    Fritzell B; Fletcher MA
    Expert Rev Vaccines; 2011 Mar; 10(3):263-90. PubMed ID: 21434795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immune response of a pneumococcal conjugate vaccine: capsular polysaccharide serotype 14-Lysine modified PspA.
    Santamaria R; Goulart C; Perciani CT; Barazzone GC; Carvalho R; Gonçalves VM; Leite LC; Tanizaki MM
    Vaccine; 2011 Nov; 29(47):8689-95. PubMed ID: 21906649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants.
    Zangwill KM; Greenberg DP; Chiu CY; Mendelman P; Wong VK; Chang SJ; Partridge S; Ward JI
    Vaccine; 2003 May; 21(17-18):1894-900. PubMed ID: 12706674
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunization with Haemophilus influenzae type b-CRM(197) conjugate vaccine elicits a mixed Th1 and Th2 CD(4+) T cell cytokine response that correlates with the isotype of antipolysaccharide antibody.
    Kamboj KK; King CL; Greenspan NS; Kirchner HL; Schreiber JR
    J Infect Dis; 2001 Oct; 184(7):931-5. PubMed ID: 11528593
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity after one, two or three doses and impact on the antibody response to coadministered antigens of a nonavalent pneumococcal conjugate vaccine in infants of Soweto, South Africa.
    Huebner RE; Mbelle N; Forrest B; Madore DV; Klugman KP
    Pediatr Infect Dis J; 2002 Nov; 21(11):1004-7. PubMed ID: 12442020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-interference between two protein carriers when used with the same polysaccharide for pneumococcal conjugate vaccines in 2-year-old children.
    Anderson P; Treanor J; Porcelli S; Pichichero M
    Vaccine; 2003 Mar; 21(13-14):1554-9. PubMed ID: 12615453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pneumococcal polysaccharide vaccine on nonbacteremic pneumococcal pneumonia.
    Weiser JN; Austrian R
    Clin Infect Dis; 2007 Apr; 44(8):1139-40; author reply 1140-1. PubMed ID: 17366469
    [No Abstract]   [Full Text] [Related]  

  • 20. [Conjugated and polysaccharide anti-pneumococcal vaccines].
    Valdez R; Sukster E
    J Pediatr (Rio J); 2005; 81(1):88. PubMed ID: 15742096
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.